The 2026 Perfect Storm: Navigating the Payer Headwinds

Clouds on the Horizon: Policy, Innovation, and Price Collide

New pricing rules. Breakthrough therapies. Shifting reimbursement models.

The health care decision-making environment in 2026 will be unlike anything payers have faced before: a perfect storm of policy, innovation, and operational change. For Managed Care Organizations (MCOs), Pharmacy Benefit Managers (PBMs), and Integrated Delivery Networks (IDNs), success will hinge on their ability to adapt quickly while keeping care accessible and affordable.

To understand where payer focus is headed, Lumanity surveyed 10 senior leaders from our Strategic Insights Panel. Their priorities reveal a year defined not by a single challenge, but by the collision of multiple forces reshaping the pharmacy landscape. Here’s what’s dominating their agenda and why it matters.

Eye of the Storm: IRA Price Negotiations and Their Ripple Effects

Among the surveyed payer leaders, there was universal agreement that the Inflation Reduction Act (IRA) and its Medicare Drug Price Negotiation provision represent the top priority for 2026. The arrival of Maximum Fair Prices (MFPs) on select Part D drugs on January 1, 2026 was not just a regulatory milestone but rather a fundamental market disruption.

Payers are acutely aware that MFPs will create significant downstream impacts. As one respondent noted, this will affect everything from “Part D formulary strategy, member cost-share, [and] contracting” to “provider prescribing patterns”. The introduction of MFPs also raises questions about the future of Average Sales Price (ASP) reimbursement for Part B drugs and how negotiated prices in Medicare might influence commercial contract expectations. Furthermore, the Part D redesign, which caps out-of-pocket spending at $2,100 and shifts 60% of the liability in the catastrophic phase to plans, places a substantial new financial toll on health plans that they must model and manage.

The Next Wave: High-Cost, High-Impact Pipeline Blockbusters

The drug pipeline remains a source of both hope and significant financial concern, with a particular focus on ultra-high-cost therapies and drugs for large populations. Three therapeutic areas stand out as a major focus for 2026:

• Oncology: Payers are preparing for a crowded pipeline of expensive innovations, including the expansion of CAR-T therapies into earlier lines of treatment and the rise of solid-tumor T-cell engagers like tarlatamab. These advancements force difficult decisions around “sequencing, outcomes, [and] total costs”. Innovation within this therapeutic category is placing increased emphasis on regimen-based therapy, resulting in a renewed focus on regimen level utilization management.
• Obesity/Metabolic Disease: The relentless advance of GLP-1s and related agents is top-of-mind. With oral formulations like orforglipron and new combinations like CagriSema on the horizon, HCDMs anticipate immense volume and budget pressure, even for plans that do not currently cover weight-loss medications.
• Cell and Gene Therapies (CGTs): Payers are closely watching the pipeline for CGTs in indications like Hunter syndrome, with one participant noting a potential price tag “above $3,000,000”. These therapies raise complex questions about coverage timing, durability, viability of risk-based contracting models, and financial sustainability of current pricing models.

Shifting Tides: The Scrutiny and Reform of PBM and Pricing Models

40% of payer leaders feel their entire business model, and every decision they make, is under a microscope. Scrutiny from federal and state legislators is fueling a potential overhaul of the traditional PBM model, with a focus on spread pricing and rebate transparency. Payers are closely monitoring legislative proposals like the Great Health Plan Bill and other reforms that could “catalyze the shift to pass-through pricing models”. Concurrently, there is continued uncertainty around potential Most Favored Nation (MFN) pricing policies, which could have a major impact on drug pricing, coverage requirements, and rebate negotiations. This intense focus on rebate models, pricing transparency, and the fundamental viability of different reimbursement structures like ASP makes 2026 a pivotal year for payment model innovation and adaptation.

Charting the Course: Steering Through the Headwinds

The Inflation Reduction Act’s price provisions may be the headline driver, but they are only part of a broader transformation. Payers will be navigating in uncharted territory, balancing blockbuster innovation with cost containment, rethinking rebate and pricing models, and responding to pressure from plan sponsors for increased transparency and interoperability.

In order for pharmaceutical manufacturers to engage effectively with payers in the year ahead they too will need to combine strategic foresight with real-time adaptability, investing in data, technology, and partnerships that can bridge policy shifts to patient impact.

At Lumanity, we help healthcare stakeholders translate payer priorities into actionable market access strategies at every stage of the product lifecycle. In a year where every decision could redefine the market, the right insights aren’t just helpful, they’re essential.

“[We are watching the] viability of ASP based reimbursement in the future due to MFP.” —Pharmacy Director, National MCO

“[Payers must consider] BCMA sequencing, outcomes, [and] total costs… [This] forces regimen-level utilization management, not single-agent PA.” —Medical Director, National MCO

“Obesity in general… we don’t cover weight-loss but the noise and buzz is important for the plan to be involved in.” —CCO, National PBM

“Continued uncertainty around potential ‘Most Favored Nation’ (MFN) pricing policies… could have major impact on drug pricing and coverage requirements [and] rebate implications as well.” —Pharmacy Director, Regional MCO